中国医药科学2025，Vol.15Issue(24)：4-9,6.DOI:10.20116/j.issn2095-0616.2025.24.01
3种检测方法比较不同基原泽泻的体外降脂活性
Comparison of three detection methods for in vitro lipid-lowering activity of Alismatis Rhizoma from different origins
摘要
Abstract
Objective To compare the differences in in vitro lipid-lowering activity of Alismatis Rhizoma from different origins and regions,providing a scientific basis for the clinical use of Alisma in treating hyperlipidemia and the development of related products.Methods The in vitro lipid-lowering activity of 30 batches of Alismatis Rhizoma samples was evaluated using three assays:sodium taurocholate binding rate,pancreatic lipase inhibition rate,and cholesterol esterase inhibition rate.Chemical pattern recognition was performed using hierarchical cluster analysis(HCA)and partial least squares-discriminant analysis(PLS-DA).Results The lipid-lowering activity of Alismatis Rhizoma exhibited significant dependence on origins and regions.HCA and PLS-DA analyses demonstrated distinct clustering patterns among samples of different origins.The established origin-discrimination model demonstrated good explanatory power and predictive ability(R2x=0.75,Q2=0.867),while the regions model displayed complete explanatory power(R2x=1)and moderate predictive ability(Q2=0.555).The Alisma orientale group generally exhibited higher cholesterol esterase inhibition rates than the Alisma plantago-aquatica group.Conclusion Alismatis Rhizoma may exerts its lipid-lowering effects primarily through cholesterol esterase inhibition,with Alisma orientale demonstrating superior activity.These findings provide experimental evidence for the selection of genuine regional medicinal materials and the development of lipid-lowering products.关键词
泽泻/东方泽泻/牛磺胆酸钠/胰脂肪酶/胆固醇酯酶/降脂活性Key words
Alismatis Rhizoma/Alisma orientale/Sodium taurocholate/Pancreatic lipase/Cholesterol esterase/Lipid-lowering activity分类
医药卫生引用本文复制引用
李晶,沈震亚,田莹莹,戴迪,谢茵,曾慧婷,柯杏,查申,杨毅生..3种检测方法比较不同基原泽泻的体外降脂活性[J].中国医药科学,2025,15(24):4-9,6.基金项目
国家自然科学基金(82460750) （82460750）
江西省药品监督管理局科研项目(2022JS36) （2022JS36）
国家药品监督管理局中成药质量评价重点实验室开放课题(JXKL-2023-03). （JXKL-2023-03）
